CSIMarket
 
Certara Inc   (NASDAQ: CERT)
Other Ticker:  
 
    Sector  Technology    Industry Software & Programming
   Industry Software & Programming
   Sector  Technology
 
Price: $14.1900 $-0.06 -0.421%
Day's High: $15.69 Week Perf: 1.36 %
Day's Low: $ 14.17 30 Day Perf: 18.65 %
Volume (M): 2,075 52 Wk High: $ 19.87
Volume (M$): $ 29,443 52 Wk Avg: $13.91
Open: $15.18 52 Wk Low: $9.41



 Market Capitalization (Millions $) 2,280
 Shares Outstanding (Millions) 161
 Employees 1,338
 Revenues (TTM) (Millions $) 370
 Net Income (TTM) (Millions $) -68
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 19

Certara Inc
We expedite medicines to patients by transforming traditional drug research and development using biosimulation software, technology, and services.
Biosimulation is a sophisticated technique that allows virtual trials to be conducted using virtual patients in order to better understand how medications respond in various persons. Throughout drug research and development, biopharmaceutical firms utilize our patented biosimulation software to guide important decisions that not only save substantial time and money but also increase drug safety and efficacy, benefitting millions of lives each year.
We build our biosimulation technology on first principles of biology, chemistry, and pharmacology with proprietary mathematical algorithms that model how medicines and diseases behave in the body. For over two decades, we have honed and validated our biosimulation technology with an abundance of data from scientific literature, lab research, and preclinical and clinical studies. In turn, our customers use biosimulation to conduct virtual trials to answer critical questions, such as: What will be the human response to a drug based on preclinical data' How will other drugs interfere with this new drug' What is a safe and efficacious dose for children, the elderly, or patients with pre-existing conditions' Virtual trials may be used to optimize dosing on populations that are otherwise difficult to study for ethical or logistical reasons, such as infants, pregnant women, the elderly, and cancer patients.
We believe that biosimulation continues to grow in adoption, driven by increasing global regulatory support and advancements in technology. We believe we are well-positioned to capture the significant market opportunity ahead of us. Our growth strategy is to build out the depth and breadth of our scalable, end-to-end biopharmaceutical platform to advance all stages of the continuum, from discovery and development to regulatory submission and market access. We continue to innovate and introduce new functionality and uses of biosimulation and technology-driven solutions. We increasingly integrate the science and data we obtain across this end-to-end platform to inform critical decisions. We further reduce the cost and time of human trials to materially accelerate the speed of development and availability of therapies to patients worldwide. As exciting, new research areas arise, we attract and hire specialized talent and acquire businesses to expand our offerings to address these market opportunities.

With continued innovation in and adoption of our biosimulation software, technology and services, we believe more biopharmaceutical companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.

Biosimulation: Biosimulation is the mathematical modeling of biological processes and systems to simulate how a drug affects the body, how the body affects the drug, how potential doses will affect different patient groups, and how patients will respond under various clinical scenarios. Biosimulation informs every stage of the drug discovery and development process and brings value through:
Identifying potential winners and losers at an earlier stage and allowing programs to 'fail faster;'
Streamlining preclinical and clinical studies or eliminating certain ones altogether;
Optimizing dosing for different populations for enhanced safety and efficacy; and
Increasing probability of success and return on R&D, amongst others.
Regulatory Science: Regulatory science is the development and application of scientific methods, tools, and approaches to support regulatory and other policy objectives. Expert management of these processes is critical to drugs receiving regulatory approval and ultimately reaching patients and generating sales. Providers of regulatory technology and expertise drive significant value for biopharmaceutical companies through:
Utilizing best-in-class technology to reduce time-intensive regulatory writing activities and the need for regulatory writing staff;
Managing submission timelines and other requirements of global regulatory agencies;
Generating clear, accurate applications and submissions; and
Developing comprehensive global regulatory strategies, amongst others.
Market Access: To achieve commercial access, sponsors must assess, optimize and persuasively communicate the value of a new therapy, both therapeutic and economic, that stakeholders such as payors and health care providers will accept and act on. Market access services, including real-world evidence and health economics outcomes research, generate value by:
Creating cost and comparative effectiveness models to support pricing and payor reimbursement;
Analyzing payor needs and using economic models to develop contracting strategies that optimize value; and
Collecting and analyzing real-world data for use in market and payor communications, amongst others. We believe that our end-to-end platform is well-positioned to continue benefiting from market trends. In addition to continued growth in our core markets, we expect to capture a broader share of overall biopharmaceutical R&D spend as we continue to innovate and add new solutions to our end-to-end platform.
Our Competitive Strengths
We compete by offering a broad and deep combination of industry-standard biosimulation software and technology-driven services across all stages of the continuum, from discovery and development to regulatory approval and market access. We have cultivated the following competitive strengths for more than two decades:
Our Proprietary, Scalable Biosimulation Software
Our proprietary, scalable biosimulation software, built on first principles integrates biosimulation models, scientific knowledge, and data, which we believe would require years of effort, immense resources, and scarce expertise to duplicate. Our versatile biosimulation software is deployed to public and private cloud networks, on-premises, and data centers. Scientists can run multiple simulation projects on a cloud compute platform or internal clusters. We protect our proprietary technology through intellectual property rights, including copyrights, patents, trade secrets, know-how, and trademarks.


   Company Address: 4 Radnor Corporate Center Radnor 19087 PA
   Company Phone Number: 237-8272   Stock Exchange / Ticker: NASDAQ CERT


Customers Net Income fell by CERT's Customers Net Profit Margin fell to

-48.58 %

17.11 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANSS   -0.9%    
ABCL        8.28% 
BRKR   -2.13%    
MASS        14.88% 
SDGR   -1.31%    
SLP   -1.06%    
• View Complete Report
   



Merger and Acquisition

Certaras Strategic Acquisition of ChemAxon: A Game Changer for Life Sciences Informatics

Published Wed, Oct 2 2024 8:15 PM UTC

Certara Completes Acquisition of ChemAxon: What It Means for the Company and Its InvestorsIn a move set to redefine its position in the life sciences industry, Certara Inc. (NASDAQ: CERT), a recognized leader in scientific software and analysis, has announced the completion of its acquisition of ChemAxon. This strategic acquisition is indicative of Certara s commitment to e...

Clinical Study

Optimizing the Future of Oncology Certara and Ichnos Glenmarks Pioneering Collaboration in Dosing Strategy for ISB 2...

Published Wed, Sep 18 2024 12:00 PM UTC

In the ever-evolving field of oncology, the quest for innovative therapies that can effectively target cancer has led to exciting collaborations aimed at optimizing drug development. A notable recent partnership is between Certara, a knowledge-based drug development company specializing in biosimulation, and Ichnos Glenmark Innovation (IGI), a biotechnology company focused o...

Merger and Acquisition

Certara Expands Horizons with ChemAxon Acquisition: A Game-Changer in Drug Discovery Software

Published Tue, Jul 9 2024 8:45 PM UTC

Certara Broadens Drug Discovery Software Portfolio with ChemAxon Acquisition
In a strategic move to enhance its drug discovery software offerings, Certara Inc. has announced its definitive agreement to acquire ChemAxon, a well-known provider of cheminformatics software. This acquisition is expected to strengthen Certara s position in the market and expand its capabilitie...

Product Service News

Certara Defies Industry Contraction with Next-Generation AI Writing Software and Revenue Growth

Published Mon, Jun 17 2024 12:00 PM UTC

Certara Unveils Next Generation AI Writing Software and Reports Revenue Increase in Q1 2024Certara, a leading provider of drug development and regulatory science software, announced the launch of its advanced CoAuthor regulatory writing software, designed specifically for medical writers. The new generation software is set to revolutionize the field by leveraging generative ...

Merger and Acquisition

Certara-Applied BioMath Merger: Creating a New Frontier in Biosimulation for Optimal Therapies' Dosing

Published Wed, Dec 13 2023 9:30 PM UTC



In a recent press release, Certara Inc, a renowned global leader in biosimulation, announced its acquisition of Applied BioMath, marking a significant expansion of its biosimulation portfolio. This strategic move aims to industrialize cutting-edge capabilities for optimal dosing of novel therapies. With this acquisition, the newly formed Certara-Applied BioMath org...







Certara Inc's Segments
Software licenses transferred at a point in time Software Licenses    10.76 % of total Revenue
Software licenses transferred over time Software Licenses    27.11 % of total Revenue
Software licenses transferred over time Service Revenue    62.13 % of total Revenue
Transferred at Point in Time Software Licenses    10.76 % of total Revenue
Transferred over Time Software Licenses    27.11 % of total Revenue
Transferred over Time Service Revenue    62.13 % of total Revenue
Americas    73.72 % of total Revenue
EMEA    19.11 % of total Revenue
Asia Pacific    7.17 % of total Revenue

  Certara Inc Outlook

On May 7 2024 the Certara Inc provided following guidance

Certara Inc. announced its financial results for the first quarter of 2024, highlighting strong performance and exceeding expectations. The company reported steady revenue growth and solid profitability during this period.

Based on these positive results, Certara Inc. is reiterating its full year 2024 financial guidance. The company remains confident in its ability to achieve its financial targets for the year and is committed to delivering value to its shareholders.

Certara Inc.'s leadership expressed optimism about the remainder of 2024, citing a strong pipeline of projects and a robust market demand for its services. The company is focused on driving innovation, expanding its customer base, ...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com